Perioperative immunotherapy in urothelial carcinoma: AMBASSADOR charts the path forward

Kriti Mittal; Monika Joshi

doi:10.1016/j.medj.2024.10.018

Perioperative immunotherapy in urothelial carcinoma: AMBASSADOR charts the path forward

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

The AMBASSADOR trial revealed improvement in disease-free survival with adjuvant pembrolizumab in patients with high-risk muscle-invasive urothelial carcinoma compared to observation.¹ In this Viewpoint, we discuss the clinical implications of these findings in the context of prior data from the CheckMate-274 and the recently published NIAGARA trial, envisioning the path forward for perioperative immunotherapy.

Original language	English (US)
Pages (from-to)	1449-1451
Number of pages	3
Journal	Med
Volume	5
Issue number	12
DOIs	https://doi.org/10.1016/j.medj.2024.10.018
State	Published - Dec 13 2024

All Science Journal Classification (ASJC) codes

General Medicine

Access to Document

10.1016/j.medj.2024.10.018

Cite this

@article{49e613f6267641e1aecc5585baa3e526,

title = "Perioperative immunotherapy in urothelial carcinoma: AMBASSADOR charts the path forward",

abstract = "The AMBASSADOR trial revealed improvement in disease-free survival with adjuvant pembrolizumab in patients with high-risk muscle-invasive urothelial carcinoma compared to observation.1 In this Viewpoint, we discuss the clinical implications of these findings in the context of prior data from the CheckMate-274 and the recently published NIAGARA trial, envisioning the path forward for perioperative immunotherapy.",

author = "Kriti Mittal and Monika Joshi",

note = "Publisher Copyright: {\textcopyright} 2024 Elsevier Inc.",

year = "2024",

month = dec,

day = "13",

doi = "10.1016/j.medj.2024.10.018",

language = "English (US)",

volume = "5",

pages = "1449--1451",

journal = "Med",

issn = "2666-6359",

publisher = "Cell Press",

number = "12",

}

TY - JOUR

T1 - Perioperative immunotherapy in urothelial carcinoma

T2 - AMBASSADOR charts the path forward

AU - Mittal, Kriti

AU - Joshi, Monika

PY - 2024/12/13

Y1 - 2024/12/13

N2 - The AMBASSADOR trial revealed improvement in disease-free survival with adjuvant pembrolizumab in patients with high-risk muscle-invasive urothelial carcinoma compared to observation.1 In this Viewpoint, we discuss the clinical implications of these findings in the context of prior data from the CheckMate-274 and the recently published NIAGARA trial, envisioning the path forward for perioperative immunotherapy.

AB - The AMBASSADOR trial revealed improvement in disease-free survival with adjuvant pembrolizumab in patients with high-risk muscle-invasive urothelial carcinoma compared to observation.1 In this Viewpoint, we discuss the clinical implications of these findings in the context of prior data from the CheckMate-274 and the recently published NIAGARA trial, envisioning the path forward for perioperative immunotherapy.

UR - https://www.scopus.com/pages/publications/85211345525

UR - https://www.scopus.com/inward/citedby.url?scp=85211345525&partnerID=8YFLogxK

U2 - 10.1016/j.medj.2024.10.018

DO - 10.1016/j.medj.2024.10.018

M3 - Comment/debate

C2 - 39674168

AN - SCOPUS:85211345525

SN - 2666-6359

VL - 5

SP - 1449

EP - 1451

JO - Med

JF - Med

IS - 12

ER -

Perioperative immunotherapy in urothelial carcinoma: AMBASSADOR charts the path forward

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this